49884-007 NDC - ASPIRIN AND EXTENDED - RELEASE DIPYRIDAMOLE CAPSULES, 25 MG / 200 MG (ASPIRIN AND EXTENDED - RELEASE DIPYRIDAMOLE)

Drug Information

Product NDC: 49884-007

Proprietary Name: Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg

Non Proprietary Name: Aspirin and Extended - Release Dipyridamole

Active Ingredient(s):
  • 25 mg/1 ASPIRIN;
  • 200 mg/1 DIPYRIDAMOLE


Administration Route(s): ORAL

Dosage Form(s): CAPSULE

Pharmacy Class(es):
  • Platelet Aggregation Inhibitor [EPC];
  • Decreased Platelet Aggregation [PE];
  • Cyclooxygenase Inhibitors [MoA];
  • Decreased Prostaglandin Production [PE];
  • Anti-Inflammatory Agents;
  • Non-Steroidal [CS];
  • Nonsteroidal Anti-inflammatory Drug [EPC];
  • Decreased Platelet Aggregation [PE];
  • Platelet Aggregation Inhibitor [EPC]

Labeler Information

Labeler Name: Par Pharmaceutical, Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: ANDA207944
Marketing Category: ANDA
Start Marketing Date:1/30/2017

Package Information

No. Package Code Package Description Billing Unit
149884-007-0260 CAPSULE in 1 BOTTLE (49884-007-02)

NDC Record

Field Name Field Value Definition
PRODUCT NDC49884-007The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEAspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mgThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEAspirin and Extended - Release DipyridamoleThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMECAPSULEThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE1/30/2017This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEANDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERANDA207944This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEPar Pharmaceutical, Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEASPIRIN; DIPYRIDAMOLEThis is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH25; 200 
ACTIVE INGRED UNITmg/1; mg/1 
PHARM CLASSESPlatelet Aggregation Inhibitor [EPC],Decreased Platelet Aggregation [PE],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC],Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 3/5/2021